Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927472 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
A Phase 3 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
NCT00927472 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 254 participants.
The verdict
NCT00927472, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
Study Summary
In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
Interventions
- DRUG Malathion gel 0.5%
- DRUG Permethrin 1% rinse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927472
The ClinicalTrials.gov registry entry for NCT00927472 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Malathion gel 0.5% is the first listed.
NCT00927472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927472 about?
NCT00927472 is a clinical study titled "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice". In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years...
What is the current status of trial NCT00927472?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2009-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00927472?
The interventions under investigation include: Malathion gel 0.5% (DRUG), Permethrin 1% rinse (DRUG).
Who is sponsoring clinical trial NCT00927472?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.